Immix Biopharma (NASDAQ:IMMX) Posts Quarterly Earnings Results, Misses Expectations By $0.01 EPS

Immix Biopharma (NASDAQ:IMMX) announced its quarterly earnings results on Thursday. The company reported ($0.19) EPS for the quarter, missing analysts’ consensus estimates of ($0.18) by ($0.01), FiscalAI reports.

Immix Biopharma Stock Performance

IMMX stock traded down $0.59 during mid-day trading on Thursday, reaching $8.07. 959,607 shares of the stock traded hands, compared to its average volume of 1,235,955. Immix Biopharma has a one year low of $3.45 and a one year high of $15.10. The stock has a market capitalization of $577.33 million, a PE ratio of -9.17 and a beta of 0.29. The business has a 50-day moving average price of $9.94 and a two-hundred day moving average price of $9.57.

Analyst Upgrades and Downgrades

IMMX has been the subject of several recent research reports. Needham & Company LLC lifted their price target on Immix Biopharma from $21.00 to $30.00 and gave the stock a “buy” rating in a research report on Tuesday, September 29th. Citigroup restated a “market outperform” rating on shares of Immix Biopharma in a research report on Wednesday, September 30th. Morgan Stanley reaffirmed an “overweight” rating on shares of Immix Biopharma in a research note on Tuesday, October 20th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Immix Biopharma in a report on Thursday, October 15th. Finally, Mizuho set a $23.00 target price on Immix Biopharma in a report on Thursday, October 29th. Eight research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $23.86.

Immix Biopharma Company Profile

Immix Biopharma is a clinical-stage biopharmaceutical company developing cell therapies for serious diseases, with a focus on relapsed or refractory AL amyloidosis, a rare condition in which abnormal proteins build up in organs and tissues. The company’s lead candidate, NXC-201, is an investigational CAR T-cell therapy designed to target BCMA, a protein found on certain plasma cells. It is being studied in clinical trials and has not been approved for commercial use. Immix Biopharma is based in the United States and is led by Chief Executive Officer Ilya Rachman.